Filing Details
- Accession Number:
- 0001567619-21-018627
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-22 21:36:35
- Reporting Period:
- 2021-10-20
- Accepted Time:
- 2021-10-22 21:36:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1630627 | Treace Medical Concepts Inc. | TMCI | Surgical & Medical Instruments & Apparatus (3841) | 471052611 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1856380 | T. John Treace | C/O Treace Medical Concepts, Inc. 203 Fort Wade Road, Suite 150 Ponte Vedra FL 32081 | Chief Executive Officer | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-10-20 | 22,612 | $24.79 | 5,894,968 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-20 | 8,215 | $25.37 | 5,886,753 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-21 | 34,325 | $19.89 | 5,852,428 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-21 | 26,701 | $20.67 | 5,825,727 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-21 | 2,768 | $21.49 | 5,822,959 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-21 | 8,207 | $23.07 | 5,814,752 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-21 | 4,044 | $23.86 | 5,810,708 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-21 | 39 | $24.50 | 5,810,669 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-22 | 57,534 | $20.74 | 5,753,135 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-22 | 555 | $21.16 | 5,752,580 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-09-07 | 408,816 | $0.00 | 408,816 | No | 4 | A | Indirect | As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Indirect | As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,605,000 | Indirect | By Wife |
| Common Stock | 1,471,250 | Indirect | By Wife as cotrustee of the JTT Irrevocable Trust dated September 30, 2020 |
| Common Stock | 1,839,063 | Indirect | As Trustee of the Tracy W. Treace Irrevocable Trust dated September 25, 2020 |
Footnotes
- Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.21 to $25.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.22 to $25.69 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.21 to $20.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.22 to $21.16 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.98 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.36 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.38 to $24.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.14 to $21.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
- The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee.
Billionaire Hedge Funds
